← Eichor
Study identifier: NCT05553093 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus  ·  Sponsor: Nanjing First Hospital, Nanjing Medical University

PhasePhase 4
Planned participants150
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.

This description comes directly from the study's public registry record.

Talk to the study team

Jianhua Ma, Doctor  ·  +862552887091  ·  majianhua196503@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Nanjing First HospitalNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05553093